NASDAQ: APGE
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing profiles in inflammatory and immunology (I&I) markets. The company's pipeline targets well-established mechanisms of action using advanced antibody engineering to optimize half-life and other properties. Its most advanced program, zumilokibart, is being developed for atopic dermatitis (the largest and one of the least penetrated I&I markets), asthma, and eosinophilic esophagitis (EoE). Apogee has five validated targets in its portfolio, pursuing best-in-class efficacy through both monotherapies and combinations of its novel antibodies. Combination programs include APG279 (zumilokibart + APG990) being studied head-to-head versus Dupixent in atopic dermatitis, and APG273 (zumilokibart + APG333), a long-acting IL-13/TSLP combination for respiratory conditions. The company is subject to a pending acquisition by AbbVie for $135.11 per share in cash, expected to close in Q3 2026. Apogee trades on Nasdaq under the ticker APGE. Updated
Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session,…
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing profiles in inflammatory and immunology (I&I) markets.
